BidaskClub cut shares of Revance Therapeutics (NASDAQ:RVNC) from a sell rating to a strong sell rating in a research note published on Wednesday morning.

RVNC has been the topic of several other reports. ValuEngine lowered Revance Therapeutics from a hold rating to a sell rating in a research report on Monday, December 4th. Cowen set a $55.00 price target on Revance Therapeutics and gave the stock a buy rating in a research report on Wednesday, January 17th. Piper Jaffray Companies raised their price target on Revance Therapeutics from $28.00 to $51.00 and gave the stock an overweight rating in a research report on Tuesday, December 5th. Mizuho restated a buy rating and issued a $54.00 price target on shares of Revance Therapeutics in a research report on Friday, January 5th. Finally, Guggenheim restated a neutral rating and issued a $42.00 price target on shares of Revance Therapeutics in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $44.30.

Revance Therapeutics (NASDAQ:RVNC) opened at $29.70 on Wednesday. The company has a market capitalization of $1,042.81, a price-to-earnings ratio of -7.82 and a beta of 1.36. Revance Therapeutics has a 12-month low of $18.00 and a 12-month high of $37.45.

In other news, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total value of $189,544.00. Following the transaction, the chief executive officer now directly owns 133,188 shares in the company, valued at approximately $3,321,708.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.86% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its holdings in Revance Therapeutics by 1.0% during the second quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock worth $604,000 after acquiring an additional 225 shares in the last quarter. Legal & General Group Plc lifted its holdings in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 438 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Revance Therapeutics by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 1,275 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in Revance Therapeutics by 6.2% during the second quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock worth $769,000 after acquiring an additional 1,711 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Revance Therapeutics by 7.9% during the third quarter. Swiss National Bank now owns 35,450 shares of the biopharmaceutical company’s stock worth $977,000 after acquiring an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/revance-therapeutics-rvnc-cut-to-strong-sell-at-bidaskclub/1858610.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.